QUANTUM GENOMICS overview

Press Realse Paris, 09 :04/2024, 18h 00 Quantum Genomics reviewed its financial situation and announced that it has filed a declaration of cessation of payment today Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) provides an update on its financial situation and announces that it has today filed a declaration of cessation of payments with the Paris Commercial Court. As a reminder, following the failure of the REFRESH Phase III trial on firibastat in October 2022, Quantum Genomics...

The Quantum Genomics Company (Euronext Growth - FR0011648971 - ALQGC) announces that, as part of its merger project with Exactcure, French HealthTech developing artificial intelligence software to adapt medication intake to the profile of each individual, the transactions concerning the reduction of its share capital and the contribution of 100% of ExactCure's shares were approved by the Shareholders at the General Meeting held on 24 April 2024. The Joint General Meeting of Shareholders of...

Press Release Paris, March 13, 2024, 6 PM Quantum Genomics publishes its results for the 2023 financial year. The merger with ExactCure, which marks the strategic redeployment of the company and will be submiCed for a shareholder vote on April 24. Quantum Genomics (Euronext Growth—FR0011648971 - ALQGC) publishes its financial results for the 2023 financial year today. The Board of Directors approved the annual accounts, which met on March 12, 2024. The audit procedures have been carried out,...

ExactCure, a private French HealthTech company developing an innovative artificial intelligence device to tailor drug administration to each individual's profile A technology with CE marking, already implemented by significant healthcare solution providers and targeting pharmaceutical laboratories Completion of the merger expected in the first quarter of 2024 Extended financial visibility until the fourth quarter of 2024, with a consolidated cash position estimated at €3 million as of the...

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) , is pleased to announce its financial results for the first half of 2023 today. The semi-annual financial statements were approved by the Board of Directors during the meeting held on October 23, 2023. The limited review procedures of the semi-annual financial information by the Auditor are complete, and their report has been published. Audited financial statements (including complete financial statements and appendices) are available on...